Related Experiment Video
Updated: Aug 11, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Postmenopausal testosterone therapy and breast cancer risk
Woraluk Somboonporn1, Susan R Davis
1Department of Obstetrics and Gynaecology, Khon Kaen University, Khon Kaen, Thailand.
Maturitas
|November 9, 2004
Summary
Testosterone may protect the breast by reducing proliferation and increasing apoptosis. However, in postmenopausal women, higher testosterone levels are linked to increased breast cancer risk, warranting caution.
Area of Science:
- Endocrinology
- Oncology
- Women's Health
Background:
- Testosterone therapy is increasingly used for postmenopausal women.
- Combined estrogen-progestin therapy increases breast cancer risk.
- The role of testosterone in breast cancer risk requires clarification.
Purpose of the Study:
- To evaluate experimental and epidemiological data on testosterone's role in breast cancer.
Main Methods:
- Comprehensive literature review.
- Analysis of studies from the Jean Hailes Foundation Research Unit.
Main Results:
- Testosterone exhibits anti-proliferative and pro-apoptotic effects via the androgen receptor (AR).
- Animal studies suggest testosterone may protect the breast from estrogen's effects.
- In premenopausal women and those with PCOS, testosterone is not linked to increased breast cancer risk.
- In postmenopausal women, higher testosterone is associated with increased breast cancer risk due to estrogen depletion and increased aromatase activity.
Conclusions:
- Testosterone may mitigate estrogen's stimulating effects on the breast when included in combined regimens.
- Testosterone therapy alone is not recommended for estrogen-deplete women due to potential aromatization to estrogen.
